Femme Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of the study is to demonstrate clinical efficacy of the investigational trifunctional bispecific antibody ertumaxomab for treatment of patients with HER-2/neu 1+ or 2+ expressing advanced or metastatic breast cancer (stage III b/IV) which has progressed during or after endocrine therapy. HER-2/neu 2+ patients must have a negative FISH test.
Critère d'inclusion
- Hormone therapy refractory advanced or metastatic breast cancer tumors (stage IIIb or IV), which are known to express HER-2/neu (1+ or 2+) and are FISH negative